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1 Introduction 
The Swiss Childhood Cancer Registry (SCCR) is a national population-based cancer registry 
for children in Switzerland. Since 1976, it registers new cancer diagnoses, clinical information 
and details on treatment and long term follow-up (survival, second tumours and late effects). 
Thereby it contributes to understanding causes of cancer in children, improving treatment and 
avoiding late effects. 
The SCCR is located at the Institute of Social and Preventive Medicine (ISPM) at the University 
of Bern and closely cooperates with the Swiss Paediatric Oncology Group (SPOG). All Swiss 
paediatric haematology-oncology clinics report each new patient to the registry and send annual 
updates thereafter. To improve completeness, since 2007, the SCCR also collects data from 
other sources (other hospitals, pathology reports, exchange of data with general cancer registries 
in cantons where these exist). By Dec 31, 2007 data from 5548 patients have been registered. 
The Swiss Childhood Cancer Registry is a member of the International Association of Cancer 
Registries (IACR) and the European Network of Cancer Registries (ENCR) and has cancer reg-
istry permission from the Swiss Federal Commission of Experts for Professional Secrecy in 
Medical Research (Eidg. Expertenkommission für das Berufsgeheimnis in der medizinischen 
Forschung), allowing collection of non-anonymised data. 
The SCCR collaborates with the National Institute for Cancer Epidemiology and Registration 
(NICER, the former Association of Swiss Cancer Registries (VSKR)), the German Childhood 
Cancer Registry in Mainz (GCCR), the National Registry of Childhood Tumours in the UK in Ox-
ford (NRCT) and other national childhood cancer registries. 
This third annual report covers routine analyses of all children diagnosed between Jan 1, 1976 
and Dec 31, 2007. Data on children diagnosed late in 2008 are not yet complete and will there-
fore be covered in the next annual report. In contrast, activities and projects of the SCCR are 
reported for the whole period Jan 2007-Jun 2009. In particular, the report contains:   
• an update on the organisation and staff of the SCCR at the Institute of Social and Preventive 
Medicine (University of Bern) and the participating paediatric haematology-oncology clinics 
of the SPOG (chapter 2) 
• a summary of the data collected in the registry until Dec 2007 (routine analyses; chapter 3) 
• current research projects of the SCCR (chapter 4)  
• review of activities Jan 2007-Jun 2009 (structural projects, database, funding, data protec-
tion; chapter 5) 
• publications (chapter 6). 
We would also like to point out our website www.childhoodcancerregistry.ch for further infor-
mation. Earlier annual reports, which can be downloaded there, contain a detailed description of 
the history of the SCCR and of past activities. 
Finally, we would like to thank all the parents and their children, all adolescent and adult child-
hood cancer survivors, and all treating physicians and data managers of the Swiss Paediatric 
Oncology Group for their excellent and lasting cooperation. We also want to give thanks to all our 
supporters for their generous contributions. Particular thanks go to the “Kinderkrebshilfe 
Schweiz”, “Novartis”, “Astrazeneca”, “Interpharma”, “AXA Winterthur” and “Glaxo SmithKline” 
who support the daily running and continuous improvement of the SCCR, and “Oncosuisse”, the 
Bernese Cancer League, the Swiss Federal Office of Health, Federal Statistical Office, Cancer 
League and the Swiss National Science Foundation for supporting our research projects. A de-
tailed list of all supporters is included in chapter 2 and in Table 11. 
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2 Organisation of the Swiss Childhood Cancer Registry 
2.1 Staff 
The Swiss Childhood Cancer Registry (SCCR) is run jointly by the Swiss Paediatric Oncology 
Group (SPOG) and the Institute of Social and Preventive Medicine (ISPM) at the University of 
Bern. 
Institute of Social and Preventive Medicine (ISPM), University of Bern 
Finkenhubelweg 11, 3012 Bern 
Tel.: +41 (0)31 631 38 99 / +41 (0)31 631 35 15 
Fax: +41 (0)31 631 36 48 
E-Mail: kinderkrebsregister@ispm.unibe.ch 
 
Scientists 
PD Dr. med. Claudia Kuehni 
FMH (Paediatrics), MSc 
(Epidemiology) 
Head of SCCR 
overall responsibility 
kuehni@ispm.unibe.ch 
Gisela Michel, PhD Research project:  
Follow-up care after childhood and 
young adult cancer 
michel@ispm.unibe.ch 
Martin Adam, MSc 
(Environmental sciences) 
Research projects: 
Completeness of SCCR / Socio-
economic status (SES) 
madam@ispm.unibe.ch 
Cornelia Rebholz, MSc 
(Environmental sciences) 
Corina Rüegg, MSc 
(Exercise & health sciences) 
Research project: 
Swiss Childhood Cancer Survivors 
Study (SCCSS) 
crebholz@ispm.unibe.ch  
 
crueegg@ispm.unibe.ch 
Marie-Pierre Strippoli, MSc 
(Medical Statistics) 
Statistician, routine analyses and 
research projects 
strippol@ispm.unibe.ch 
 
Administration, medical documentation and computer science 
Marianne Reck Responsible for donations mreck@ispm.unibe.ch 
Myriam Pyrlik Medical documentalist, SCCR Data 
Manager  
mpyrlik@ispm.unibe.ch 
Dr. med. Elisabeth Kiraly  Diagnostic Coding kiraly@ispm.unibe.ch 
Gerrit Viehmann Medical documentalist, Study Data 
Manager 
gviehmann@ispm.unibe.ch 
Malcolm Sturdy  Computer Science sturdy@ispm.unibe.ch 
Philipp Läuppi Web-Design and Web-Administration plaeuppi@ispm.unibe.ch 
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Swiss Paediatric Oncology Group (SPOG) 
SPOG Office  
Effingerstrasse 40, 3008 Bern 
Tel.: +41 (0)31 389 91 89  
Fax: +41 (0)31 389 92 00  
 
SPOG Executive 
  
PD Dr. med. Nicolas von der Weid President Nicolas.Von-Der-Weid@chuv.ch 
Prof. Dr. med. Felix Niggli Vice President felix.niggli@kispi.uzh.ch 
Dr. med. Heinz Hengartner Secretary heinz.hengartner@kispisg.ch 
 
Central office in Bern 
  
Isabelle Lamontagne-Müller Managing director, clini-
cal trials, ethic committee 
submissions 
isabelle.lamontagne@spog.ch 
Barbara Kindler Central administration barbara.kindler@spog.ch 
 
Participating clinics (Haemato-Oncology) 
 Head of Division Local Data Manager 
Aarau (Kinderklinik, Kantonsspital 
Aarau) 
Dr. med. R. Angst Dr. med. R. Angst 
Basel (Universitätskinderspital beider 
Basel) 
Prof. Dr. med. M. 
Paulussen 
V. Stahel 
Bern (Universitäts-Kinderklinik, 
Inselspital) 
Prof. Dr. med. A. Hirt F. Julmy  
N. Beusch 
Genève (Hôpital des Enfants, HUG) PD Dr. med. H. Ozsahin M. Berner 
Lausanne (Service de Pédiatrie, 
CHUV) 
PD Dr. med. M. Beck-
Popovic 
Dr. med. R.-E. Garcia 
Tessin 
Locarno (Reparto di Pediatria, 
Ospedale Regionale di Locarno) 
(until Dec 2007) 
 
Dr. med. L. Nobile 
 
Dr. med. L. Nobile 
Bellinzona (Reparto di Pediatria, 
Ospedale S. Giovanni, Bellinzona) 
Dr. med. P. Brazzola Dr. med. P. Brazzola 
Luzern (Kinderspital, Kantonspital 
Luzern) 
Dr. med. U. Caflisch Y. Bonetti 
St.Gallen (Ostschweiz. Kinderspital) Dr. med. J. Greiner F. Hochreutner 
Zurich (Universitäts-Kinderklinik, 
Zürich) 
Prof. Dr. med. F. Niggli H. Markiewicz 
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2.2 General information 
The SCCR is an associate member of the International Association of Cancer Registries (IACR) 
and the European Network of Cancer Registries (ENCR). 
Inclusion criteria and data collection 
The SCCR registers all children and adolescents diagnosed with: i) Acute and chronic leukae-
mias, including myelodysplastic syndrome, ii) all solid malignancies, iii) all central nervous sys-
tem tumours (CNS), including benign tumours, iv) Langerhans cell histiocytosis (LCH) and other 
histiocytosis (type I–III). Most children are reported from one of the nine Swiss clinics for paediat-
ric oncology and haematology. A small proportion of patients (<10% of children aged <16 years) 
is treated in other hospitals, and information related to these cases is collected via other sources 
(cantonal cancer registries, other hospitals, pathologies, death certificates). We aim for complete 
registration of all children below the age of 16 years. Patients aged between 16 and 19 years are 
also registered, but registration is not complete because these adolescents are usually not 
treated in paediatric clinics. Children who are not residents of Switzerland but come here for 
treatment are also registered, but excluded from analyses of incidence and survival.   
Follow-up data is extracted once or twice a year from the patients’ hospital records for the first 5 
to 10 years after diagnosis. Thereafter follow-up data are obtained from the patients’ general 
practitioners or paediatricians. Very long-term follow-up occurs via direct contact to patients (see 
chapter 4: Swiss Childhood Cancer Survivor Study) and data linkage with mortality records and 
cantonal cancer registries. In each of the nine centres a local data manager completes the data 
forms. These are sent to the SCCR and entered into the database. Important documents (e.g. 
pathology reports) are scanned and saved under a pseudonym (ID number). Paper copies are 
destroyed.   
Database 
The new electronic database of the SCCR was developed by Malcolm Sturdy in 2006-2007. At 
present, the following information on cancer patients is being collected: 
• Patient name, current address and phone number, and address at the time of diagnosis 
• Name and address of the general practitioner or paediatrician and the paediatric oncology 
clinic treating the child 
• Demographic information (date of birth, gender) 
• Socio-economic information (parental profession, place of origin, country of residence) 
• Tumour diagnosis, date of diagnosis, type of cancer, histology, stage, metastases 
• Other diagnoses, relevant pre-existing disease conditions 
• Clinical information and relevant laboratory values 
• Treatment (treatment protocols, medication and dosages, radiotherapy, surgical interven-
tions, others) 
• Follow-up data concerning change of treatment, remission, relapses, survival/death and 
cause of death 
• Late effects due to malignancy and therapy 
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Tumour coding 
Until 2004, all tumours were coded according to the American Paediatric Oncology Group (POG). 
In addition, the exact diagnosis including details on location and staging was recorded. Since 
2004 the SCCR codes new tumours according to the following international classifications (see 
Appendix):  
1. The third edition of the International Classification of Childhood Cancer (ICCC-3)1 
2. The third edition of the International Classification of Diseases for Oncology (ICD-O-3)2 
3. The tenth edition of the International Statistical Classification of Diseases and Related 
Health Problems (ICD-10)3 
Between 2004 and 2006, all tumours contained in the database were double-coded by two phy-
sicians according to the three new classification systems. To achieve this, all essential original 
reports (pathology, histology, radio-diagnostics) were collected from the hospital archives. 
For presentation of data in the annual report we use the following classification for general diag-
nostic groups – a summary from the ICCC-3 classification: I. Leukaemias, II. Lymphomas, III. 
Central nervous system (CNS) neoplasms, IV. Neuroblastoma, V. Retinoblastoma, VI. Renal 
tumours, VII. Hepatic tumours, VIII. Malignant bone tumours, IX. Soft tissue sarcomas (STS), X. 
Germ cell tumours, XI. Other malignant epithelial neoplasms, XII. Other and unspecified malig-
nant neoplasms. Langerhans cell histiocytoses (LCH), which are not contained in ICCC-3, are 
reported separately. 
Completeness  
Incidence of childhood cancers in the SCCR is similar to published incidence in cantonal cancer 
registries and in neighbouring countries (France, Germany and Italy).4 This suggests that 
completeness of cases registered in the SCCR is comparable to neighbouring countries. Even 
CNS neoplasms, a problematic diagnostic group in many paediatric cancer registries, are rela-
tively well covered, amounting to 24% of all cancers in 2001–2005. A first study in the 1980s, 
comparing completeness of the SCCR to cantonal general cancer registries, mortality statistics 
and hospital archives, suggested that in 1985-1988 the SCCR included 91% of all leukaemia 
cases recorded by the six existing cantonal registries and 80% of deaths due to childhood leu-
kaemia in the mortality statistics in 1989.5 In 2006-2008, a new validation study was performed 
by linking the SCCR with datasets from the cantonal cancer registries (Basel, Geneva, Grisons 
and Glarus, Valais, St.Gallen and Appenzell, Ticino, Zurich). This linkage suggested that in the 
period 1990 to 2004, 22% of children registered in the cantonal registries had not been registered 
in the SCCR (manuscript submitted for publication). Of these, 6% had been treated in a paediat-
ric cancer centre of the Swiss Paediatric Oncology Group, but had not been reported to the 
SCCR, and 16% had been treated in other hospitals, including smaller children’s clinics or adult 
wards. The proportion of patients not treated in a paediatric cancer centre decreased from 24% 
in 1990-1993 to 7% in 2002-2004. All missed patients who have been identified by this study 
have since been registered in the SCCR. Also, because of these findings, the SCCR now regis-
ters patients from various other sources besides paediatric cancer centres, via regular data ex-
change with cantonal cancer registries, and data collection from other hospitals, pathologies and 
mortality statistics. As a consequence the data protection situation changed and the SCCR re-
ceived a general exemption instead of special exemption (see chapter 2.2.5).   
                                                     
1
 Steliarova-Foucher E, Stiller C, Lacour B, Kaatsch P. International Classification of Childhood Cancer, Third Edition. 
Cancer 2005;103(7):1457-67. 
2
 World Health Organization. International Statistical Classification of Diseases for Oncology - Third Edition (ICD-O-
3). Geneva: World Health Organization; 2000. 
3
 World Health Organization. International Statistical Classification of Diseases and Related Health Problems - Tenth 
Revision. Geneva: World Health Organization; 1993. 
4
 Michel G, von der Weid N, Zwahlen M, Redmond S, Strippoli MPF, Kuehni CE. Incidence of childhood cancer in 
Switzerland: the Swiss Childhood Cancer Registry. Pediatr Blood Cancer 2008;50:46-51. 
5
 Morin G, Ackermann Liebrich U, Imbach P. Childhood leukaemia in Switzerland: comparison of different sources of 
data. Soz Praeventivmed. 1993;38:196–201. 
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Data protection 
Between 2004 and 2007, the SCCR has had a special exemption (“Sonderbewilligung”) from the 
Swiss Federal Commission of Experts for Professional Secrecy in Medical Research. During this 
period, written informed consent was collected from new patients and those still in follow-up.   
Since June 2007, the Swiss Childhood Cancer Registry has general registry approval by the 
Swiss Federal Commission of Experts for Professional Secrecy in Medical Research. This ap-
proval permits the collection of data on cancer in children and adolescents throughout Switzer-
land without obtaining written consent. At the time of diagnosis all patients and their parents are 
informed by their doctor about the registry and they can ask their treating doctor not to forward 
their data (veto power). Records of these patients are completely anonymised. Huge efforts were 
made to inform all patients and their families, and all physicians in Switzerland about the registry, 
using various approaches (publications in official medical journals, oral presentations, letters to 
hospitals, physicians and parents organisations, and publications on the internet and in major 
newspapers). Information for patients is also available from hospital brochures, hospital notice 
boards, and parents and patients organisations. The patient data are kept strictly confidential in 
accordance with the requirements of the Data Protection Act and data with personal information 
(names, addresses) are kept separately from the medical information. 
Further information on this permission can be obtained from the homepage of the Swiss Federal 
Commission of Experts for Professional Secrecy in Medical Research, at the Federal Office of 
Health. A copy of the document provided by the expert commission can be downloaded from our 
homepage (http://www.childhoodcancerregistry.ch/index.php?id=2451), together with pub-
lications in French and German explaining the data protection measures, and text proposals for 
insertion in patient information brochures of hospitals and for short patient information on notice 
boards in German, French and Italian. 
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Funding 
The SCCR thanks the following supporters for their generous unrestricted financial support for 
daily running and continuous development of the registry. Supporters of scientific research pro-
jects are listed in Table 11 page 33. 
Enduring supporters  
Kinderkrebshilfe Schweiz  
 
Swiss Paediatric Oncology Group 
(SPOG)  
Current supporters 08/09  
Stiftung für krebskranke Kinder Regio 
Basiliensis  
 
Novartis 
 
GlaxoSmithKline 
 
AstraZeneca 
 
Interpharma ph 
 
AXA Winterthur 
 
Amgen 
 
CSL Behring 
 
Essex Chemie AG 
 
Pfizer  
 
Past supporters 06/07  
Schweizerische Stiftung für klinische 
Krebsforschung (SSKK) 
 
Stiftung zur Förderung von sozialen 
Massnahmen in der Kranken- und Un-
fallversicherung 
 
Bristol-Myers Squibb 
 
Baxter 
 
Mundipharma 
 
Valiant Bank 
 
Sanitas Versicherungen 
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3 Routine analyses covering cases diagnosed between 
1976-2007 
The section on routine analyses includes three chapters. 
Chapter 3.1 describes the whole database, i.e. all children registered in the SCCR from 1976 to 
Dec 31, 2007 with a diagnostic code contained in ICCC-3 or a Langerhans cell histiocytosis 
(LCH), irrespective of age at diagnosis. This also includes adolescents older than 14 years, who 
are often treated in adult clinics and therefore only incompletely reported to the SCCR. Also in-
cluded in this chapter are children resident in other countries who came to Switzerland for diag-
nostic work-up and treatment. 
Chapter 3.2 includes the core group of children aged 0-14 years at diagnosis and resident in 
Switzerland at the time of diagnosis. This is the age group usually covered in international publi-
cations, and tables and figures can therefore be compared directly to data from other countries. 
Case registration in Switzerland is rather complete for this age range and incidence data can 
therefore be calculated. 
Chapter 3.3 describes numbers of patients reported by different clinics of the SPOG for various 
periods irrespective of age and country of residence. 
3.1 All cases registered in the SCCR (N=5548) 
This chapter contains summary statistics for all children registered between Jan 1976 and Dec 
2007. For children diagnosed in Nov or Dec 2008, some information (e.g. on treatment) is incom-
plete, and other information has not yet been validated (such as country of residence). For these 
reasons, data on children diagnosed in 2008 will be covered in the next annual report. 
By Dec 31, 2007 a total of 5548 tumour cases with a diagnostic code contained in ICCC-3 or a 
Langerhans cell histiocytosis (LCH) had been registered in the SCCR. Of these, 4878 (88%) 
were Swiss residents at the time of diagnosis and 521 (9%) were foreign residents who came to 
Switzerland for treatment. For 149 children (3%) country of residence was unknown (Table 1). 
For retinoblastoma, 56% (156/277) of cases were foreign residents. This is mainly due to the 
Jules Gonin Eye Hospital at the University Hospital in Lausanne, which has treated 198 of the 
total 288 cases of retinoblastoma. 
Systematic registration of all patients participating in clinical trials started in 1976 and the number 
of patients registered per year increased considerably after non-trial patients were included in 
1981 (Figure 1). After 1994 annual registration increased only slightly. In the years 2006-2007, a 
total of 414 new patients were registered, 366 of whom were Swiss residents at the time of diag-
nosis (Table 2). For comparability with international datasets, only data from Swiss residents 
aged 0-14 years at diagnosis are included in further analyses. 
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Table 1 – Total number of registered cases in the SCCR, by country of 
residence 
(including all age groups, all diagnoses (ICCC-3 or Langerhans cell histiocytosis), years of diag-
nosis 1976-2007 (N=5548)) 
 
 All ages 0-14 years >14 years 
Country of residence n % n % n % 
1 Switzerland 4878 87.9 4539 87.7 339 91.6 
2 Other countries 521 9.4 501 9.7 20 5.4 
a Europe 371 6.7 359 6.9 12 3.2 
 Neighbouring countries* 228 4.1 217 4.2 11 3.0 
 Other European countries 143 2.6 142 2.7 1 0.3 
b Middle East 10 0.2 10 0.2 0 0.0 
c North Africa 78 1.4 72 1.4 6 1.6 
d Other African countries 37 0.7 36 0.7 1 0.3 
e Other countries 25 0.5 24 0.5 1 0.3 
3 Country of residence missing 149 2.7 138 2.7 11 3.0 
TOTAL 5548 100.0 5178 100.0 370 100.0 
* Austria (N=7), France (N=59), Germany (N=50), Italy (N=101), Liechtenstein (N=11) 
 
Figure 1 – Total number of cases registered in the SCCR  
(including all age groups, all diagnoses (ICCC-3 or Langerhans cell histiocytosis), years of diag-
nosis 1976-2007 (N=5548)) 
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Table 2 – Number of cases registered in the SCCR (5-year intervals) 
(including all age groups, all diagnoses (ICCC-3 or Langerhans cell histiocytosis), years of diag-
nosis 1976-2007 (N=5548)) 
 
Year of diagnosis All patients Swiss residents, per period 
Swiss residents, 
per year 
until 1980 487 420 105 
1981-1985 658 566 113 
1986-1990 786 638 128 
1991-1995 1030 902 180 
1996-2000 1050 942 188 
2001-2005 1123 1044 201 
2006-2007* 414 366 183 
TOTAL 5548 4878 157 
*numbers for 2006-2007 are lower because this row includes only a two-year period, while the other rows include a five-
year period of data collection. 
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3.2 All cases aged 0-14 years at diagnosis resident in 
Switzerland (N=4539) 
This chapter includes only data on children aged 0-14 years and resident in Switzerland at diag-
nosis. This is the age group usually covered in international publications, and tables and figures 
can therefore be compared directly to data from other countries. Case registration in Switzerland 
is rather complete for this age range and incidence data can be calculated. 
As of Dec 31, 2007 the SCCR contained data on 4539 children who were aged 0-14 years and 
who were resident in Switzerland at the time of diagnosis. Of these, 1105 (24%) had died and 
847 (19%) were lost to follow-up. For 1494 cases (33%), the last follow-up information was re-
ported after Jan 2005, for 501 (11%) and 592 (13%) the last follow-up information was collected 
in the period 2000–2004, and before the year 2000 respectively (Table 3). Currently (2008-2010) 
we are updating long-term follow-up information for all patients, using two approaches: active 
follow-up of survivors with postal questionnaires in the Swiss Childhood Cancer Survivor Study 
and systematic assessment of mortality via contacts with community registries and linkage with 
the Swiss mortality statistics (see chapter 4, research projects). 
Nearly half of the cases (46%) had been diagnosed at the age of 0-4 years, 36% at the age of 1-
4 years and 10% during infancy (less than 1 year of age) (Table 4 and Figure 2). The number of 
cases per age group declines from infancy to age 9 years and increases again in older children 
(Figure 3 and Figure 4). 
One third of childhood cancers diagnosed in Swiss children between 1976 and 2007 were leu-
kaemias (35%), followed by central nervous system neoplasms (18%) and lymphomas (14%, 
Table 5 and Figure 5). 
 
 
Table 3 – Number of patients in the SCCR databases 
(Swiss residents, aged 0-14 years at diagnosis, all diagnoses (ICCC-3 or Langerhans cell histio-
cytosis), years of diagnosis 1976-2007 (N=4539)) 
 
Follow-up status n % 
Died 1105 24.3 
Last follow-up since Jan 2005 1494 32.9 
Last follow-up 2000-2004 501 11.0 
Last follow-up before 2000 592 13.0 
Lost to follow-up 847 18.7 
TOTAL 4539 100.0 
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Table 4 / Figure 2 – Age at first diagnosis  
(Swiss residents, aged 0-14 years at diagnosis, all diagnoses (ICCC-3 or Langerhans cell histio-
cytosis), years of diagnosis 1976-2007 (N=4539)) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Age in years n % 
< 1 year 473 10.4 
1 – 4 years 1635 36.0 
5 – 9 years 1217 26.8 
10 – 14 years 1214 26.8 
TOTAL 4539 100.0 
< 1 year 
10%
1 – 4 years 
36%
 
 
10 – 14 
years 
27%
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Figure 3 – Age at first diagnosis  
(Swiss residents, aged 0-14 years at diagnosis, all diagnoses (ICCC-3 or Langerhans cell histio-
cytosis), years of diagnosis 1976-2007 (N=4539)) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4 – Age at first diagnosis, by sex  
(Swiss residents, aged 0-14 years at diagnosis, all diagnoses (ICCC-3 or Langerhans cell histio-
cytosis), years of diagnosis 1976-2007 (N=4539))  
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Table 5 – Diagnostic groups according to ICCC-3  
(Swiss residents, aged 0-14 years at diagnosis, all diagnoses (ICCC-3 or Langerhans cell histiocytosis), years of diagnosis 1976-2007 (N=4539)) 
  
 
Total Age group 
Diagnosis n <1yr 1-4yrs 5-9yrs 10-14yrs 
I Leukaemias, myeoloproliferative diseases and myelodysplastic diseases 1588 60 763 448 317 
II Lymphomas and reticuloendothelial neoplasms 618 16 93 182 327 
III Central nervous system neoplasms 798 58 234 291 215 
IV Neuroblastoma and other peripheral nervous cell tumours 298 135 125 26 12 
V Retinoblastoma 121 57 55 8 1 
VI  Renal tumours 256 39 150 59 8 
VII  Hepatic tumours 42 13 15 5 9 
VIII Malignant bone tumours 189 0 17 57 115 
IX Soft tissue and other extraosseous sarcomas 275 31 78 73 93 
X Germ cell tumours, trophoblastic tumours and neoplasms of gonads 112 22 28 14 48 
XI Other malignant epithelial neoplasms and malignant melanomas 60 4 8 12 36 
XII Other and unspecified malignant neoplasms 12 2 3 1 6 
 Langerhans cell histiocytosis 170 36 66 41 27 
TOTAL 4539 473 1635 1217 1214 
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Figure 5 – Diagnostic groups according to ICCC-3  
(Swiss residents, aged 0-14 years at diagnosis, all diagnoses (ICCC-3 or Langerhans cell histio-
cytosis), years of diagnosis 1976-2007 (N=4539)) 
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Diagnosis according to ICCC-3 for all cases registered in the SCCR 
between 1998-2007 
Table 6 reports detailed information on diagnosis according to ICCC-3 for all cases registered in 
the SCCR during the past 10 years (1998-2007). Relative frequency of the different diagnoses, 
sex ratio, mean age at diagnosis and age-standardised incidence are very similar to results from 
Germany.6  
As found in other childhood cancer registries there were a higher number of boys than girls. This 
was true for most types of tumours with the exception of neuroblastoma, germ cell tumours and 
other malignant epithelial neoplasms. 
The age-standardised incidence of any childhood cancer (not including Langerhans cell histio-
cytosis) in the past 5 years was 21.7 cases per 100,000 person/years in Switzerland (age-stan-
dardisation according to the world population for the age-groups under 15 years7). Age adjusted 
incidence was highest among children aged less than 1 year with 37.2 cases per 100,000 per-
son/years and lowest in 9 year olds and older with 16.7 cases per 100,000 person/years 
(Figure 6 showing crude incidence rates and Figure 7 showing age- and sex-specific incidence 
rates). 
 
                                                     
6
 Kaatsch P, Spix C. Annual report 2008: German Childhood Cancer Registry (GCCR). Mainz; 2009 
7
 Parkin DM, Kramarova E, Draper GJ, Masuyer E, Michaelis J, Neglia J, et al. The international incidence of childhood 
cancer, Vol II. Lyon: IARC Scientific Publications; 1998. 
Table 6 – Number of registered cases in the SCCR, sex ratio, mean age at diagnosis and age-standardised incidence* (per 
100,000 person/years), by diagnostic groups according to ICCC-3  
(Swiss residents, aged 0-14 years at diagnosis, all diagnoses (ICCC-3 or Langerhans cell histiocytosis), years of diagnosis 1998-2007 (N=1795)) 
 
  
n Relative % Sex Ratio (M:F) Mean age Incidence* 
I Leukaemias, myeloproliferative diseases and myelodysplastic diseases 565 32.6 1.4 4.8 46.5 
 a. Lymphoid leukaemias 459 81.2 1.3 4.6 37.7 
 b. Acute myeloid leukaemias 73 12.9 1.6 5.4 6.0 
 c. Chronic myeloproliferative diseases 4 0.7 3.0 9.2 0.3 
 d. Myelodysplastic syndrome and other myeloproliferative diseases 19 3.4 1.1 8.8 1.6 
 e. Unspecified and other specified leukaemias 10 1.8 1.5 3.5 0.8 
II Lymphomas and reticuloendothelial neoplasms 212 12.2 1.9 10.3 17.4 
 a. Hodgkin lymphomas 88 41.5 1.1 12.7 7.2 
 b. Non-Hodgkin lymphomas (except Burkitt lymphoma) 84 39.6 2.1 9.0 6.9 
 c. Burkitt lymphoma 35 16.5 7.8 7.3 2.9 
 d. Miscellaneous lymphoreticular neoplasms 4 1.9 3.0 0.9 0.3 
 e. Unspecified lymphomas 1 0.5 0.0 13.6 0.1 
III CNS and miscellaneous intracranial and intraspinal neoplasms 397 22.9 1.2 6.7 32.6 
 a. Ependymomas and choroid plexus tumour 30 7.6 0.9 2.1 2.5 
 b. Astrocytomas 151 38.0 1.3 7.2 12.4 
 c. Intracranial and intraspinal embryonal tumours 103 25.9 1.6 5.7 8.5 
 d. Other gliomas 41 10.3 1.0 5.9 3.4 
 e. Other specified intracranial and intraspinal neoplasms 67 16.9 0.9 9.7 5.5 
 f. Unspecified intracranial and intraspinal neoplasms 5 1.3 0.7 9.5 0.4 
IV Neuroblastoma and other peripheral nervous cell tumours 109 6.3 0.9 0.9 9.0 
 a. Neuroblastoma and ganglioneuroblastoma 109 100.0 0.9 0.9 9.0 
V Retinoblastoma 41 2.4 1.0 0.9 3.4 
VI Renal tumours 97 5.6 1.2 2.9 8.0 
 a. Nephroblastoma and other nonepithelial renal tumours 94 96.9 1.3 2.8 7.7 
 b. Renal carcinomas 2 2.1 0.0 13.7 0.2 
  c. Unspecified malignant renal tumours 1 1.0 0.0 12.8 0.1 
Table 6 – continued 
 
  
n Relative % Sex Ratio (M:F) Mean age Incidence* 
VII Hepatic tumours 22 1.3 2.1 1.4 1.8 
 a. Hepatoblastoma 17 77.3 3.3 1.1 1.4 
 b. Hepatic carcinomas 5 22.7 0.7 13.7 0.4 
VIII Malignant bone tumours 92 5.3 0.9 10.9 7.6 
 a. Osteosarcomas 47 51.1 0.8 11.7 3.9 
 c. Ewing tumour and related sarcomas of bone 45 48.9 1.0 10.6 3.7 
IX Soft tissue and other extraosseous sarcomas 118 6.8 1.4 8.4 9.7 
 a. Rhabdomyosarcomas 73 61.9 2.0 5.8 6.0 
 b. Fibrosarcomas, peripheral nerve sheath tumours and other fibrous neoplasms 6 5.1 1.0 0.1 0.5 
 d. Other specified soft tissue sarcomas 26 22.0 0.9 11.9 2.1 
 e. Unspecified soft tissue sarcomas 13 11.0 0.6 7.9 1.1 
X Germ cell tumours, trophoblastic tumours, and neoplasms of gonads 46 2.7 0.8 7.7 3.8 
 a. Intracranial and intraspinal germ cell tumours 10 21.7 2.3 9.5 0.8 
 b. Malignant extracranial and extragonadal germ cell tumours 11 23.9 0.2 0.4 0.9 
 c. Malignant gonadal germ cell tumours 23 50.0 0.9 10.3 1.9 
 d. Gonadal carcinomas 2 4.3 1.0 13.0 0.2 
XI Other malignant epithelial neoplasms and malignant melanomas 34 2.0 1.3 11.2 2.8 
 a. Adrenocortical carcinomas 2 5.9 1.0 4.2 0.2 
 b. Thyroid carcinomas 10 29.4 1.5 12.6 0.8 
 d. Malignant melanomas 13 38.2 0.6 6.5 1.1 
 e. Skin carcinomas 2 5.9 0.0 7.2 0.2 
 f. Other and unspecified carcinomas 7 20.6 2.5 11.1 0.6 
XII Other and unspecified malignant neoplasms 1 0.1 0.0 12.9 0.1 
 a. Other specified malignant tumours 1 100.0 0.0 12.9 0.1 
  
Total (not including Langerhans cell histiocytosis) 1734 100.0 1.3 6.6 142.6 
 
Langerhans cell histiocytosis 61 3.4 1.1 5.8 5.0 
  
Total (including Langerhans cell histiocytosis) 1795 100.0 1.3 5.7 147.6 
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Figure 6 – Crude incidence rate (per 100,000 person/years) in Switzerland 
(Swiss residents, aged 0-14 years at diagnosis, not including Langerhans cell histiocytosis, years 
of diagnosis 1990-2007 (N=3024)) 
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Figure 7 – Age- and sex-specific incidence rates (per 100,000 person/years) 
in Switzerland 
(Swiss residents, aged 0-14 years at diagnosis, not including Langerhans cell histiocytosis, years 
of diagnosis 1998-2007 (N=1735)) 
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3.3 Cases reported by the 9 centres of the SPOG  
Tables 7 and 8 show the distribution of patients reported from the 9 SPOG clinics, for the periods 
1976-1997 (Table 7) and 1998-2007 (Table 8) respectively. Table 9a and Table 9b show the 
numbers reported from the different SPOG clinics in the year 2006 (Table 9a) and 2007 (Table 
9b) respectively. 
All patients irrespective of age and residency (Swiss and foreign patients) are included in these 
tables. 
Table 7 – Diagnosed* childhood cancer cases between 1976 and 1997, by participating oncology clinic  
(including all age groups, all diagnoses (ICCC-3 or Langerhans cell histiocytosis), years of diagnosis 1976-1997 (N=3402)) 
All patients irrespective of age and residency (Swiss and foreign patients) are included in this analysis. 
 
  Total Aarau Basel Bern Geneva Lausanne Locarno Lucerne StGallen Zurich Unknown‡ 
  Diagnosis n % n % n % n % n % n % n % n % n % n % n % 
I Leukaemias 1161 100 81 7.0 114 9.8 302 26.0 99 8.5 120 10.3 19 1.6 91 7.8 120 10.3 203 17.5 12 1.0 
II Lymphomas 493 100 36 7.3 46 9.3 117 23.7 41 8.3 69 14.0 11 2.2 30 6.1 39 7.9 92 18.7 12 2.4 
III Central nervous system neoplasms 495 100 27 5.5 34 6.9 170 34.3 43 8.7 60 12.1 10 2.0 10 2.0 38 7.7 83 16.8 20 4.0 
IV Neuroblastoma 232 100 7 3.0 22 9.5 44 19.0 24 10.3 39 16.8 0 0.0 17 7.3 18 7.8 56 24.1 5 2.2 
V Retinoblastoma† 172 100 0 0.0 7 4.1 17 9.9 16 9.3 103 59.9 2 1.2 8 4.7 9 5.2 8 4.7 2 1.2 
VI Renal tumours 183 100 5 2.7 16 8.7 43 23.5 14 7.7 23 12.6 0 0.0 18 9.8 17 9.3 46 25.1 1 0.5 
VII Hepatic tumours 28 100 0 0.0 2 7.1 10 35.7 2 7.1 4 14.3 0 0.0 0 0.0 1 3.6 9 32.1 0 0.0 
VIII Malignant bone tumours 179 100 6 3.4 27 15.1 52 29.1 23 12.8 29 16.2 2 1.1 6 3.4 13 7.3 15 8.4 6 3.4 
IX Soft tissue sarcomas 197 100 7 3.6 17 8.6 49 24.9 12 6.1 32 16.2 3 1.5 17 8.6 22 11.2 32 16.2 6 3.0 
X Germ cell tumours 98 100 7 7.1 8 8.2 23 23.5 10 10.2 13 13.3 2 2.0 2 2.0 5 5.1 26 26.5 2 2.0 
XI Other malignant epithelial neoplasms 34 100 1 2.9 2 5.9 10 29.4 5 14.7 7 20.6 1 2.9 1 2.9 1 2.9 3 8.8 3 8.8 
XII Other and unspecified malignant neoplasms 12 100 0 0.0 1 8.3 2 16.7 0 0.0 3 25.0 0 0.0 0 0.0 0 0.0 1 8.3 5 41.7 
 Langerhans cell histiocytosis 118 100 6 5.1 14 11.9 30 25.4 4 3.4 14 11.9 1 0.8 8 6.8 21 17.8 20 16.9 0 0.0 
  TOTAL 3402 100 183 5.4 310 9.1 869 25.5 293 8.6 516 15.2 51 1.5 208 6.1 304 8.9 594 17.5 74 2.2 
* Diagnosis coded according to ICCC-3 
† Most cases with retinoblastoma are treated at the specialised Jules Gonin Eye Hospital at the University Hospital in Lausanne 
‡ Treating institution unknown 
 
Table 8 – Diagnosed* childhood cancer cases between 1998 and 2007, by participating oncology clinic  
(including all age groups, all diagnoses (ICCC-3 or Langerhans cell histiocytosis), years of diagnosis 1998-2007 (N=2146))  
All patients irrespective of age and residency (Swiss and foreign patients) are included in this analysis. 
 
  Total Aarau Basel Bern Geneva Lausanne Locarno Lucerne StGallen Zurich Unknown‡ 
  Diagnosis n % n % n % n % n % n % n % n % n % n % n % 
I Leukaemias 640 100 45 7.0 49 7.7 111 17.3 44 6.9 89 13.9 16 2.5 43 6.7 69 10.8 166 25.9 8 1.3 
II Lymphomas 273 100 18 6.6 20 7.3 49 17.9 19 7.0 46 16.8 7 2.6 32 11.7 25 9.2 52 19.0 5 1.8 
III Central nervous system neoplasms 451 100 23 5.1 26 5.8 90 20.0 33 7.3 85 18.8 13 2.9 4 0.9 37 8.2 125 27.7 15 3.3 
IV Neuroblastoma 122 100 5 4.1 14 11.5 16 13.1 8 6.6 23 18.9 1 0.8 9 7.4 12 9.8 34 27.9 0 0.0 
V Retinoblastoma† 105 100 0 0.0 4 3.8 3 2.9 2 1.9 85 81.0 0 0.0 2 1.9 2 1.9 5 4.8 2 1.9 
VI Renal tumours 103 100 9 8.7 11 10.7 16 15.5 11 10.7 10 9.7 4 3.9 5 4.9 10 9.7 27 26.2 0 0.0 
VII Hepatic tumours 25 100 4 16.0 2 8.0 3 12.0 2 8.0 3 12.0 2 8.0 0 0.0 3 12.0 5 20.0 1 4.0 
VIII Malignant bone tumours 125 100 5 4.0 22 17.6 17 13.6 15 12.0 28 22.4 3 2.4 3 2.4 8 6.4 22 17.6 2 1.6 
IX Soft tissue sarcomas 141 100 13 9.2 13 9.2 21 14.9 12 8.5 23 16.3 2 1.4 12 8.5 10 7.1 30 21.3 5 3.5 
X Germ cell tumours 54 100 7 13.0 3 5.6 5 9.3 5 9.3 12 22.2 1 1.9 6 11.1 5 9.3 7 13.0 3 5.6 
XI Other malignant epithelial neoplasms 44 100 3 6.8 4 9.1 4 9.1 2 4.5 3 6.8 1 2.3 4 9.1 7 15.9 8 18.2 8 18.2 
XII Other and unspecified malignant neoplasms 3 100 0 0.0 0 0.0 1 33.3 1 33.3 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 33.3 
 Langerhans cell histiocytosis 60 100 5 8.3 5 8.3 12 20.0 2 3.3 12 20.0 3 5.0 2 3.3 7 11.7 12 20.0 0 0.0 
  TOTAL 2146 100 137 6.4 173 8.1 348 16.2 156 7.3 419 19.5 53 2.5 122 5.7 195 9.1 493 23.0 50 2.3 
* Diagnosis coded according to ICCC-3 
† Most cases with retinoblastoma are treated at the specialised Jules Gonin Eye Hospital at the University Hospital in Lausanne 
‡ Treating institution unknown 
 
Table 9a – Diagnosed* childhood cancer cases in 2006, by participating oncology clinic  
(including all age groups, all diagnoses (ICCC-3 or Langerhans cell histiocytosis), new patients diagnosed in 2006 (N=215)) 
All patients irrespective of age and residency (Swiss and foreign patients) are included in this analysis. 
 
  Diagnosis Total Aarau Basel Bern Geneva Lausanne Locarno Lucerne StGallen Zurich Unknown‡ 
I Leukaemias 55 6 3 11 1 6 1 5 8 13 1 
II Lymphomas 35 5 4 8 2 5 2 2 2 3 2 
III Central nervous system neoplasms 41 0 1 9 1 10 1 1 3 15 0 
IV Neuroblastoma 14 0 2 1 1 4 0 2 0 4 0 
V Retinoblastoma† 11 0 0 0 0 8 0 1 0 0 2 
VI Renal tumours 14 1 1 2 1 0 0 1 1 7 0 
VII Hepatic tumours 1 0 0 0 1 0 0 0 0 0 0 
VIII Malignant bone tumours 12 0 1 1 2 3 1 0 1 2 1 
IX Soft tissue sarcomas 16 2 1 3 4 1 1 2 1 1 0 
X Germ cell tumours 6 1 2 0 0 0 0 1 1 1 0 
XI Other malignant epithelial neoplasms 5 0 0 0 0 1 0 0 2 1 1 
XII Other and unspecified malignant neoplasms 1 0 0 1 0 0 0 0 0 0 0 
 Langerhans cell histiocytosis 4 1 0 2 0 1 0 0 0 0 0 
  TOTAL 215 16 15 38 13 39 6 15 19 47 7 
* Diagnosis coded according to ICCC-3 
† Most cases with retinoblastoma are treated at the specialised Jules Gonin Eye Hospital at the University Hospital in Lausanne 
‡ Treating institution unknown 
 
Table 9b – Diagnosed* childhood cancer cases in 2007, by participating oncology clinic 
(including all age groups, all diagnoses (ICCC-3 or Langerhans cell histiocytosis), new patients diagnosed in 2007 (N=199)) 
All patients irrespective of age and residency (Swiss and foreign patients) are included in this analysis. 
 
  Diagnosis Total Aarau Basel Bern Geneva Lausanne Locarno Lucerne St. Gallen Zurich Unknown‡ 
I Leukaemias 73 3 6 12 5 15 1 5 9 16 1 
II Lymphomas 31 4 3 6 0 5 0 6 3 3 1 
III Central nervous system neoplasms 35 2 2 5 1 12 0 0 0 11 2 
IV Neuroblastoma 12 1 1 3 1 0 0 0 2 4 0 
V Retinoblastoma† 9 0 0 0 0 9 0 0 0 0 0 
VI Renal tumours 6 1 1 1 0 0 0 0 1 2 0 
VII Hepatic tumours 1 0 0 0 0 0 0 0 0 1 0 
VIII Malignant bone tumours 8 0 1 0 0 4 0 0 0 3 0 
IX Soft tissue sarcomas 10 0 1 1 0 2 0 1 2 2 1 
X Germ cell tumours 3 0 0 0 0 2 0 0 0 1 0 
XI Other malignant epithelial neoplasms            
XII Other and unspecified malignant neoplasms 4 0 0 0 1 0 0 1 1 1 0 
 Langerhans cell histiocytosis 7 1 1 0 0 2 0 0 3 0 0 
  TOTAL 199 12 16 28 8 51 1 13 21 44 5 
* Diagnosis coded according to ICCC-3 
† Most cases with retinoblastomas are treated at the specialised Jules Gonin Eye Hospital at the University Hospital in Lausanne 
‡ Treating institution unknown 
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4 Current research projects at the SCCR 
The section on current research projects at the SCCR includes two chapters. 
Chapter 4.1 lists studies conducted in one or several centres of the Swiss Paediatric Oncology 
Group, to which the SCCR contributed data or performed statistical analyses. 
Chapter 4.2 describes past or current research projects, which are conducted at the SCCR.   
 
 
4.1 Collaboration in research projects of the SPOG 
This concerns projects initiated and led by members of the Swiss Paediatric Oncology Group 
(single centre and multi centre projects, MD theses and PhD theses) where the SCCR contrib-
uted, by extracting data from the SCCR database or participating in data analysis and interpreta-
tion. 
Table 10 includes a list of these projects since 2005 with related publications.   
 
 
4.2 Research projects conducted at the SCCR  
This relates to research projects which are initiated and conducted by the SCCR, using mainly 
data from the SCCR, newly collected data and often comparison data from other national data-
sets (such as the Swiss National Cohort or the Swiss Health Surveys).  
Table 11 lists all research projects conducted at the SCCR since 2005, finished projects as well 
as ongoing projects. Subsequently, some are described in more detail. Additional information is 
available from the references and from the investigators. We thank all sponsors of the projects. 
 
Table 10 – Collaboration in studies conducted by Swiss Paediatric Oncology Group since 2005 
 
No Title Investigator Population Data extracted Date of 
extraction 
Publications 
1 Survival of childhood 
cancer in the past 30 
years in Zurich 
F. Niggli,  
Zurich 
All patients from Zurich with 
follow-up information 
(N=650) 
Diagnosis, age, sex, date of 
diagnosis, death and last 
follow-up. Cox regression and 
Kaplan Meyer curves 
Mar 05 Oral presentation, University 
Children’s Hospital, Zurich 
2 Retinoblastoma 
treatment in 
Switzerland 
M. Beck-Popovic, 
Lausanne 
All patients with 
retinoblastoma who were 
registered in the SCCR 
(n=245) 
Year of diagnosis, treating 
institutions 
Aug 05 Wallach M. et al.: Shorter time to 
diagnosis and improved stage at 
presentation in Swiss patients with 
retinoblastoma treated from 1963 to 
2004. Pediatrics 2006;118:e1493-8.  
3 Number of patients 
with Ewing sarcoma of 
Rhabdomyosarcoma 
M. Paulussen, 
Basel 
All patients with Ewing 
sarcoma or 
rhabdmyosarcoma 
diagnosed from 2000 to 
2004 
Diagnosis, year of diagnosis Dec 05 Kreuter M. et al.: Clinical significance 
of Vascular Endothelial Growth 
Factor-A expression in Ewing’s 
sarcoma. Eur J Cancer 
2006;42:1904-11. 
4 Leukaemia in 
Switzerland 
J-P. Bourquin, 
Lausanne 
All leukaemia cases in 
Switzerland since 1994 
(N=811)  
Diagnosis, year of diagnosis, 
sex 
Jun 06 Oral presentations 
5 Renal tumours in 
Switzerland 
M. Diezi,  
Lausanne 
All patients with renal 
tumours registered in the 
SCCR from 1992-2004 
(N=145) 
Diagnosis, date of birth and 
diagnosis, age at diagnosis, 
annual incidence 
Oct 06 Diezi M. et al.: Renal tumours in 
children. Rev Med Suisse 
2007;3:360-2, 364-5. French 
6 Craniopharyngeoma 
patients in Bern 
M. Janner,  
Bern 
All patients with a 
craniopharyngeoma from 
Bern (N=17) 
Names, dates of birth and 
diagnosis, sex 
Jan 07 Presentation internal meeting, 
University Children’s Hospital, Bern 
Table 10 – continued 
 
No Title Investigator Population Data extracted Date of 
extraction 
Publications 
7 Childhood acute myeloid 
leukaemias (AML): the 
clinical significance of 
cytogenetic events at 
presentation and relapse 
D. Betts,  
Zurich 
All patients with AML 
registered in the SCCR 
(N=103) 
All information on patient, 
tumour and therapy levels. 
Calculation of survival. 
Feb 07 Betts DR. et al.: The prognostic 
significance of cytogenetic 
aberrations in childhood acute 
myeloid leukaemia. A study of the 
Swiss Paediatric Oncology Group 
(SPOG); Eur J Haematol. 
2007;78:468-76. 
8 Wilms Tumour, Soft 
tissue sarcoma (STS) 
and autologous bone 
marrow transplantation 
(BMT) 
N. von der Weid, 
Lausanne 
All patients with Wilms 
tumour of STS who had 
autologous bone marrow 
transplantation  
Diagnosis, year of diagnosis, 
autologous BMT 
May 07 Retrospective request of EBMT 
registry 
9 Patients with diagnosis 
date between 01.11.06–
31.10.07 
N. von der Weid, 
Lausanne 
 Diagnosis, year of diagnosis, 
year of relapse 
Feb 08 Annual report SPOG 
10 Medulloblastoma and 
trisomy 21 
N. von der Weid, 
Lausanne 
All patient with 
medulloblastoma and prior 
relevant diseases (trisomy 
21)  
Diagnosis and prior relevant 
diseases 
Nov 08 Publication in preparation 
(international collaboration) 
11 Primitive 
neuroectodermal tumour 
(PNET) and trisomy 21 
N. von der Weid, 
Lausanne 
All patient with PNET and 
prior relevant diseases 
(trisomy 21) 
Diagnosis and prior relevant 
diseases 
Dec 08 Publication in preparation 
(international collaboration) 
12 Patients with diagnosis 
date between 01.11.07–
31.10.08 
N. von der Weid, 
Lausanne 
 Diagnosis, year of diagnosis, 
year of relapse 
Feb 09 Annual report SPOG 
13 Current address research 
for patients from cerebral 
tumour database Zurich 
M. Grotzer,  
Zurich 
Address from patients with 
cerebral tumour 
Current addresses Mar 09 Project ongoing 
Table 11 – Research projects of the SCCR since 2005 
 
No Project name Funding Primary investigator Study Type Study period 
1 Follow-up care after childhood and young adult cancer Swiss National Science Foundation Michel G Cohort study 08.2009-07.2012 
2 Childhood Cancer and Nuclear Power Plants in Switzerland - 
CANUPIS 
Swiss Federal Office of Health / 
Swiss Cancer League 
Kuehni CE Cohort study 09.2008-03.2011 
3 Swiss Childhood Cancer Survivor Study (SCCSS) Oncosuisse von der Weid NX 
Kuehni CE 
Cohort study  01.2006-08.2010 
4 Childhood leukaemia and lymphoma: are incidence and survival in 
Switzerland associated with socio-economic status?  
Oncosuisse Zwahlen M Cohort study 08.2007-07.2009  
5 An international case-control study on brain tumours in children 
and adolescents - CEFALO 
Swiss Research Foundation on 
Mobile Communication / Swiss 
Federal Office of Health 
Roeoesli M Cohort study 10.2005-12.2008 
6 Completeness of cancer registration and diagnostic accuracy in 
the Swiss Childhood Cancer Registry: validation against inde-
pendent sources of data 
Bernese Cancer League Egger M Cohort study 06.2006-08.2007  
 
7 Validating date and cause of death information in the SCCR 
against death certificate information from the Swiss Federal Sta-
tistical Office 
Swiss Federal Statistical Office Kuehni CE Cohort study 2005 
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Project 1 - Follow-up care after childhood and young adult cancer 
This is a survey of long-term survivors (≥ 5 years) of childhood cancer, oncologists, haematolo-
gists and family practitioners in Switzerland, to assess current use of follow-up care and prefer-
ences/opinions for a future Swiss model of follow-up care. 
Background: Treatment for cancer in children and young adults has greatly improved and most 
patients are being cured. However, more than 50% of survivors of childhood cancer suffer from 
late effects. To detect and treat late effects as early as possible it is important that survivors 
continue to visit follow-up care long after they have been cured from the cancer. Various models 
of follow-up care have been described but so far none has been implemented in Switzerland. 
While follow-up care needs to be constantly updated according to the current status of research, 
it is also important that it is convenient for survivors to participate. 
Aims: 1) Compare advantages and disadvantages of follow-up care models currently used in 
Europe. 2) Determine the current availability and use of follow-up care in survivors of childhood 
and young adult cancer in Switzerland. 3) Determine the advantages and disadvantages of fol-
low-up care models as perceived by survivors, oncologists and family practitioners, and compare 
their views and opinions. 
Methods: Part 1 will comprise a questionnaire survey of clinics and follow-up programs to assess 
the models of care currently used in Europe. In part 2, current use of follow-up care together with 
their psychological well-being will be determined in childhood cancer survivors using data from 
the Swiss Childhood Cancer Survivor Study. In part 3, a questionnaire survey will assess opin-
ions and perspectives on currently used and desired optimal follow-up care. The sample will 
include cancer survivors who were diagnosed with cancer between 1990 and 2005 and aged 
under 25 years, who have survived for more than 5 years and who are currently aged 11 years 
and older. In addition paediatric and adult oncologists and haematologists, and family practitio-
ners will fill in a questionnaire. 
Rationale and significance: This project will give an overview of follow-up care models used in 
Europe and describe the preferences for follow-up care models in survivors, oncologists and 
family practitioners in Switzerland. Differences between the three groups will be determined in 
order to improve follow-up care in the future, adapting it to the differing preferences. The project 
will provide the basis for the development of a standardised model of follow-up care for childhood 
cancer survivors in Switzerland. 
 
Study Team 
Applicant: Michel G. Institute of Social and Preventive Medicine, University of Bern. Project 
team: Michel G, Kuehni CE, Egger M, Viehmann G. Institute of Social and Preventive Medicine, 
University of Bern; Von der Weid N. Paediatric Oncology, CHUV Lausanne; Niggli F. University 
Children’s Hospital, Zurich. 
 
Collaborations  
Skinner R, Kremer L, Frey E, Levitt G, Bardi E. PANCARE (European collaboration on follow-up 
care after childhood cancer); Eiser C, Greenfield D. Child and Family Research Group, University 
of Sheffield. 
 
Publications expected for 2011. 
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Project 2 - Childhood Cancer and Nuclear Power Plants in Switzerland - 
CANUPIS 
This study addresses the question if residence in the proximity of a nuclear power plant (NPP) is 
associated with an increased risk of childhood cancer, and whether this can be explained by con-
founding, particularly by other area-based risk factors for childhood cancer which might cluster 
around nuclear power plants. Details are available from the dedicated CANUPIS-Homepage: 
www.canupis.ch 
Background: Since the reporting of a cluster of leukaemia cases around Sellafield in 1984, nu-
merous studies have assessed the risk of childhood cancer and residence in the proximity of nu-
clear power plants (NPPs). These studies showed heterogeneous results, many with weak posi-
tive associations. An explanation for this excess is lacking. Emissions from NPPs during normal 
operation are low in comparison to the annual background exposure and dose-response studies 
do not support a causal association. A recent case-control study from Germany, showing a small 
but statistically significant increase in the risk of cancer, particularly leukaemia, in children aged 
less than five years living near NPPs refuelled the public discussion about this potential hazard. 
The study, as many others, had methodological problems limiting the interpretability of the re-
sults, including i) a potential selection bias because of differential response rates of municipali-
ties; ii) possible bias due to selection of controls by local clerks; iii) lack of adjustment for poten-
tial confounding factors such as electric power lines, major roads, socio-economic status, and 
other factors; and iv) analysis of residency at the time of cancer diagnosis only (because of the 
known latency in development of malignant diseases, the place of residence prior to the diagno-
sis is of great interest). 
Aims: To investigate whether living near a NPP increases the risk of childhood cancer in general, 
and childhood leukaemia in particular. 
Methods: This is a census-based cohort study with national coverage. Selection bias is mini-
mized by using geocoded addresses for each child, important potential confounders will be ad-
justed for, and residential history back to the date of birth will be included. The study uses the 
Swiss National Cohort (SNC), a long-term, census-based, multipurpose cohort and research 
platform including all Swiss inhabitants (6.8 million people) to estimate person-years at risk. 
Cases are identified via the Swiss Childhood Cancer Registry (SCCR). Included are all patients 
born between Jan 1985 and Dec 2007, aged less than16 years at diagnosis and resident in 
Switzerland. 
Our main exposure is proximity to nuclear sites modelled as four categories (the inner 5 km zone, 
5-10 km, 10-15 km and more than15 km). The following confounders are included: Distance to 
major roads, electric power lines and broadcast transmitters, natural ionising radiation, area 
statistics (e.g. pesticides from agriculture or golf courses), pollutants from industry, degree of 
urbanisation, socio-economic status (using the Sotomo-Index) and average number of children 
per family at communal level. 
Rational and significance: This study will add importantly to the current evidence base on the 
risk of childhood cancer and residence in the proximity of nuclear sites. It will overcome important 
methodological problems of previous studies. Given the fact that additional nuclear sites are cur-
rently planned in Switzerland, the topic is of high public health and policy relevance. 
 
 
Study Team 
Applicants: Von der Weid N. Paediatric Oncology, CHUV Lausanne; Niggli F. University Chil-
dren’s Hospital, Zurich; Hengartner H. Ostschweizer Kinderspital, St. Gallen; Egger M. Institute of 
Social and Preventive Medicine, University of Bern. Project team: Feller M, Kuehni CE, Güler A, 
Viehmann G, Spring-Rüesch M, Röösli M, Huss A. Institute of Social and Preventive Medicine, 
University of Bern 
 
Publications expected for 2011. 
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Project 3 - Swiss Childhood Cancer Survivor Study (SCCSS) 
This is a follow-up survey of all long-term survivors (≥ 5 years after diagnosis) of childhood can-
cer in Switzerland, to assess somatic and psychosocial late effects and health-related quality of 
life. 
Background: Thanks to therapeutic improvements in the past decades, survival rates in child-
hood cancer have increased to 75-80%, resulting in a growing population of long-term survivors. 
However, cancer and cancer treatments have been associated with adverse late effects. There-
fore, health and quality of life of survivors are a matter of increasing concern. In Switzerland and 
elsewhere, comprehensive data on the burden of late effects of childhood cancer and its risk 
factors, and data on use of follow-up care in long-term survivors are scarce. 
Aims: This project investigates the long-term outcome of former childhood cancer patients who 
were diagnosed with cancer before age 16 and survived for more than 5 years. It studies inci-
dence of various somatic outcomes (late mortality, secondary malignancies, endocrine disorders, 
infertility, cardiovascular events) and health related quality of life (HRQoL), and their association 
with a number of risk factors assessed prospectively at the time of diagnosis (tumour, treatment 
modalities, demographic characteristics). In addition, current practice of health-care provision 
and health behaviour in long-term survivors are investigated. 
Methods: This is a prospective cohort study based on the population of children registered in the 
Swiss Childhood Cancer Registry (SCCR). The SCCR contains 5866 records on childhood can-
cer patients (Sep 2008). Eligible for the study are 2900 individuals, who have been diagnosed 
before May 1, 2003 (i.e. at least 5 years prior to beginning of the study) have survived for more 
than 5 years and are Swiss residents. The age range at the time of the study is 5 to 49 years. 
A detailed questionnaire is being sent to all participants, assessing demographic and socio-eco-
nomic information, educational and professional achievements, current medical conditions and 
treatments, HRQoL, health behaviour and healthcare provision. Sub-samples of participants from 
the major diagnostic groups reporting potentially relevant events will be interviewed in more detail 
by phone. If consent is given, questionnaire data will be complemented with and validated 
against general practitioners and hospital records. 
Rationale and significance: The existing database of the SCCR gives the rare opportunity for a 
nationwide study of long-term outcomes in survivors of childhood cancer. The project will in-
crease the knowledge on incidence and risk factors of late effects and provide a summary of the 
current status of care in Switzerland. As many late effects can be prevented or cured if diag-
nosed early, this study will also contribute to improving the health of current and future survivors 
of childhood cancer. 
 
Study team 
Applicants: Von der Weid N. Paediatric Oncology, CHUV Lausanne; Kuehni CE, Egger M, 
Zwahlen M. Institute of Social and Preventive Medicine, University of Bern; Probst-Hensch N. 
Dept. of Pathologie / Dept. of Social and Preventive Medicine, University Hospital, Zurich; Niggli 
F. University Children’s Hospital, Zurich. Project team: Rebholz C, Rueegg C, Plym A, Kuehni 
CE, Michel G. Institute of Social and Preventive Medicine, University of Bern; Von der Weid N. 
Paediatric Oncology, CHUV Lausanne; Niggli F. University Children’s Hospital, Zurich 
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Publications 
Original peer-reviewed papers  
Michel G, Rebholz CE, von der Weid NX, Bergstraesser E, Kuehni CE. Psychological distress in 
adult survivors of childhood cancer: the Swiss Childhood Cancer Survivor Study. submitted. 
 
Published abstracts  
Essig S, Rebholz CE, Strippoli MPF, Michel G, Von der Weid NX, Niggli FK, Kuehni CE. Long-
term childhood ALL survivors: Health-related quality of life after a relapse. Swiss Med Wkly 2009 
Rueegg CS, Rebholz CE, Strippoli MPF, Michel G, Von der Weid NX, Niggli FK, Kuehni CE. 
Physical activity levels among Swiss childhood cancer survivors. Swiss Med Wkly 2009 
Rebholz CE, von der Weid NX, Michel G, Niggli FK, Kuehni CE. Follow-up care in long-term 
childhood cancer survivors in Switzerland: who is missed out? Swiss Med Wkly 
2008;138(Suppl.164):4S  
Kuehni CE, Rebholz CE, Michel G, Adam M, Niggli FK, von der Weid NX. Educational level and 
employment of Swiss childhood cancer survivors, Swiss Med Wkly 2008;138(Suppl.164):26S  
Rebholz CE, Von Der Weid NX, Michel G, Niggli FK, Kuehni CE. Smoking behaviour among 
Swiss childhood cancer survivors, Swiss Med Wkly 2008;138(Suppl 164):26S 
Michel G, Rebholz CE, von der Weid NX, Bergstraesser E, Kuehni CE. Psychological distress in 
long-term survivors of childhood cancer in Switzerland. Psychology and Health 2008;23(S1):184 
Rebholz CE, Kuehni CE, Michel G, von der Weid NX. The Swiss Childhood Cancer Survivor 
Study: Aims, methods and preliminary results. Swiss Med Wkly 2007;137(Suppl. 158):6S  
  
35 
Project 4 - Childhood leukaemia and lymphoma: are incidence and survival 
in Switzerland associated with socio-economic status?  
The research project aims to investigate the association of socio-economic status (SES) with the 
risk of developing childhood leukaemia or childhood lymphoma, and to explore whether the as-
sociation is varying with the operational definition of socio-economic status. 
Aims: 1) To investigate the association of socio-economic status with the risk of developing 
childhood leukaemia or childhood lymphoma, and to explore whether the association is varying 
with the operational definition of socio-economic status. 2) To investigate the association of 
socio-economic status with the five-year survival rate for cases of childhood leukaemia or child-
hood lymphoma. 
Methods: The two main aims are addressed by a case-control study design (for the association 
between SES and risk of disease) and by a prospective cohort study design of the included 
cases (for the differentials in mortality and survival). The study includes all cases of childhood 
leukaemia or lymphoma reported to the SCCR and diagnosed between 1991 and 2006 with a 
year of birth such that the diseased child has been recorded either in the 1990 or in the year 
2000 census (approximately 700 leukaemia and 300 lymphoma cases). The restriction on being 
recorded in one of the censuses is needed to use the census information on profession and edu-
cation of the child’s parents thus obtaining relevant information on SES. Furthermore we are us-
ing information about the living conditions (number of rooms per person in the household, owner-
ship of house or apartment) from the census data. Additionally, we use recently developed (So-
tomo-Index, www.sotomo.geo.unizh.ch) area-based SES measures that are defined by the 
community in which a person lives. To obtain the SES information from the census records we 
have developed methodologically sound probabilistic record linkage procedures that relate the 
cancer cases and the census records of all residents in Switzerland. For the case-control study 
we have selected for each case 10 control children from the two census rounds. We thus can 
include approximately 1000 cases and 10,000 control subjects in the case-control part of the 
study. Analysis is being performed by logistic regression and time-to-event analyses (life-table, 
Kaplan-Meier estimates and proportional hazards models). 
Rationale and significance: Childhood leukaemia and childhood lymphoma comprise about half 
of all cancer diagnoses in children. Therefore, assessing SES as a risk factor for this subgroup is 
of public health importance. Using the population-based childhood cancer registry in this study is 
unlikely to be hampered by biases involved in studying only selected subsets of cases. 
 
Study team 
Applicants: Zwahlen M, Egger M, Kuehni CE. Institute of Social and Preventive Medicine, Uni-
versity of Bern; Von der Weid N. Paediatric Oncology, CHUV Lausanne. Project team: Adam M, 
Zwahlen M, Kuehni CE, Spörri A, Schmidlin K. Institute of Social and Preventive Medicine, Uni-
versity of Bern  
 
Publications 
Original peer-reviewed papers  
Adam M, Rebholz CE, Egger M, Zwahlen M, Kuehni CE. Childhood leukemia and socioeconomic 
status: what is the evidence? Radiat Prot Dosim 2009;132:246-54. 
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Project 5 - An international case-control study on brain tumours in children 
and adolescents – CEFALO 
Background: It has been hypothesized that children could be more vulnerable to radio frequency 
electromagnetic field exposures from mobile telephones than adults, but no epidemiological stud-
ies of the relationship have been performed so far. The lack of knowledge causes conflicting rec-
ommendations from decision-makers, leading to anxiety and insecurity in the population. WHO 
has put a case-control study on childhood brain tumours as high priority on their 2006 research 
agenda on radio frequency electromagnetic fields. 
Objectives: The main goal of the study is to investigate whether use of mobile telephones in-
creases the risk of developing brain tumours for children or adolescents. In addition, our study 
will provide a comprehensive dataset to investigate other potential risk factors for childhood brain 
tumour. 
Study design: The questions under study are being investigated by means of a case-control 
study in Denmark, Norway, Sweden and Switzerland. Cases were identified through a combina-
tion of registry data and information from the wards treating the patients (e.g. Swiss Paediatric 
Oncology Group). All incident cases of brain tumour in the age group 7-19 years between May 
2004 and Apr 2008 were invited to participate. In total, the study is expected to include 550 cases 
of brain tumours in the participating countries, thereof 100 originating from Switzerland. For each 
case, two control persons have been randomly selected from the general population, matched on 
age, sex and geographic regions. 
Exposure assessment: Information on the extent of exposure to radio frequency fields from mo-
bile phones and on other known and suspected risk factors for childhood brain tumours is ob-
tained by means of computer assisted personal interviews conducted by an interviewer trained 
for this purpose. The interviews took place either at the hospital or at the study participant’s 
home. Objective information on the frequency and duration of mobile phone use is being ob-
tained from mobile phone operators and from the information stored in the telephone that is in 
current use. 
Data analyses: The data are being analyzed using established statistical methods for case-con-
trol studies, primarily via logistic regression models adjusted for potential confounding factors. In 
order to investigate potential gene-environment interactions, DNA from saliva samples is being 
extracted and analysed. Polymorphisms in genes that affect oxidative metabolism, detoxification 
of carcinogens, DNA stability and repair, or immune response, are candidates that might confer 
genetic susceptibility to brain tumours. 
 
Study team   
Applicants: Röösli M, Kuehni CE. Institute of Social and Preventive Medicine, University of Bern; 
Grotzer M. University Children’s Hospital, Zurich; Feychting M. Karolinska Institute, Stockholm; 
Tynes T. Cancer Registry of Norway, Oslo; Von der Weid N. Paediatric Oncology, CHUV 
Lausanne; Schütz J. Institute of Cancer Epidemiology, University of Bielefeld. Project Team: 
Aydin D, Röösli M, Jenni D, Rey D. Institute of Social and Preventive Medicine, University of 
Basel; Kuehni CE, Michel G. Institute of Social and Preventive Medicine, University of Bern. 
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Publications 
Original peer-reviewed papers  
Kheifets L, Repacholi M, Saunders R, van Deventer E. The sensitivity of children to electromag-
netic fields. Pediatrics 2005;116(2): e303-13  
 
Published abstracts  
Feychting M for the CEFALO Study Group. A case-control study of brain tumours in children and 
adolescents and mobile phone use. Symposium at the Joint Conference of the International 
Society for Environmental Epidemiology (ISEE) and the International Society for Exposure As-
sessment (ISEA), Sep 2-6, 2006, Paris. Epidemiology 2006;17(6):S74. 
 
Conference or workshop abstracts  
Schüz, J, Feychting, M, Röösli M, Tynes T, Samsø Schmidt L, Johansen C, Prohazka M, Sverin 
E, Jenni D, Kuehni CE, Klaboe L. An international case-control study on mobile phone use and 
the risk of brain tumours in children and adolescents (Cefalo study): a report from the field work 
and first results on mobile phone usage among children. 8th International Congress of the Euro-
pean Bioelectromagnetics Association (EBEA), Bordeaux 10-13 Apr 2007. 
Röösli M for the CEFALO Study Group. An international case-control study on mobile phone use 
and the risk of brain tumours in children and adolescents (Cefalo study): study design and first 
experiences from the field work. Scientific Workshop hosted by the FGF: Do Children Represent 
a Special Sensitive Group for EMF-Exposure? - State of Research. Stuttgart, 27-29 Nov 2006. 
(www.cost281.org)  
 
Other publications  
Röösli M. Ursachen von Hirntumouren bei Kindern und Jugendlichen. Jahresbericht 2006 der 
Forschungsstiftung Mobilkommunikation; p. 22-23.  
(http://www.mobile-research.ethz.ch/var/jb2006.pdf)  
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Project 6 - Completeness of cancer registration and diagnostic accuracy in 
the Swiss Childhood Cancer Registry: validation against independent 
sources of data 
The research project has validated and compared patient records in the SCCR against data reg-
istered in cantonal cancer registries in Switzerland.   
Aims: This research project aimed to validate and complete records of the SCCR against inde-
pendent sources of data, particularly cantonal registries of the Association of Swiss Cancer Reg-
istries (ASRT). Particularly, we aimed to determine what proportion of childhood cancer patients 
was not treated in a Swiss Paediatric Cancer Centre (PCC), to describe the characteristics of 
these patients and to find out where they had been cared for. 
Methods: The Swiss Childhood Cancer Registry (SCCR) registers all children treated in Swiss 
PCCs. The cantonal (=regional) cancer registries (existing in 14/26 cantons) register all cancer 
patients of a canton. We compared the children of both registries, using specialized software for 
record linkage. All children aged <16 years at diagnosis with primary malignant tumours, diag-
nosed and registered between 1990 and 2004, and living in cantons covered by a cantonal reg-
istry were included in the analysis. For patients with imperfect matches, a chart review in the 
central archive of the SPOG and in participating clinics was performed to identify data entry er-
rors. 
Results: 22.1% (238/1077) of patients recorded in cantonal registries were not registered in the 
SCCR. Of these, 15.7% (169/1077) had never been in a PCC while 6.4% (69/1077) had been in 
a PCC but were not registered in the SCCR, due to incomplete data flow. All age groups and all 
diagnoses were involved, but children suffering from malignant bone tumours/soft tissue sarco-
mas and from malignant epithelial neoplasms, and older children were least likely to have been 
treated in a PCC. The proportion of patients treated in a PCC increased over time (p<0.0001) 
such that in 2000-2004, only 8,9% were not treated in a PCC. 
Rationale and significance: A comparatively high proportion of childhood cancer patients in 
Switzerland was not treated in a PCC and may therefore have not received best available care. 
Based on these findings we are currently developing a standardised protocol for regular future 
cross-validation between these databases, and we have begun to recruit cases from other 
sources than PCCs (cantonal cancer registries, pathology reports, other hospitals). 
 
Study team 
Applicants: Egger M, Kuehni CE. Institute of Social and Preventive Medicine, University of Bern; 
Ess S. VSKR, St. Gallen; Von der Weid N. Paediatric Oncology, CHUV Lausanne. Project team: 
Adam M, Kuehni CE, Zwahlen M, Michel G. Institute of Social and Preventive Medicine, Univer-
sity of Bern; Von der Weid N. Paediatric Oncology, CHUV Lausanne  
 
Publications 
Original peer-reviewed papers  
Adam M, von der Weid NX, Michel G, Zwahlen M, Lutz JM, Probst-Hensch NM, Niggli F and 
Kuehni CE for the Swiss Paediatric Oncology Group (SPOG) and for the Swiss Association of 
Cancer Registries (ASRT). Which childhood cancer patients fail to access specialized care? 
submitted. 
Michel G, von der Weid NX, Zwahlen M, Adam M, Rebholz CE, Kuehni CE. The Swiss Childhood 
Cancer Registry: Rationale, organisation years 2001-2005. Swiss Med Wkly 2007;137(Suppl.35-
36):502-9. 
 
Published abstracts  
Adam M, Von Der Weid NX, Michel G, Zwahlen M, Ess S, Kuehni CE. Which childhood cancer 
patients fail to access specialised paediatric oncology care? Swiss Med Wkly 2008;138:39S. 
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Project 7 - Validating date and cause of death information in the SCCR 
against death certificate information from the Swiss Federal Statistical 
Office 
Aims: This study matched the Swiss Childhood Cancer Registry (SCCR) patients (N=4856) to 
information from official death certificates recorded by the Swiss Federal Statistical Office 
(SFSO), to validate SFSO death certificate information and to update information on vital status 
in the SCCR using an independent information source. 
Methods: First, anonymous records from both databases were matched using probabilistic re-
cord linkage techniques. For cases with discordant or missing information, further analysis was 
performed to identify predictors and possible causes for the discrepancy, using detailed demo-
graphic, clinical and healthcare information provided in the SCCR database. Where necessary, 
an additional chart review using the SPOG central archive and hospital records was performed. 
Results: These are summarized in the final report, which can be obtained from the authors. 
 
Study team 
Applicants: Kuehni CE, Zwahlen M, Egger M. Institute of Social and Preventive Medicine, Uni-
versity of Bern; Von der Weid N. Paediatric Oncology, CHUV Lausanne. Project team: Michel G, 
Sturdy M, Strippoli MPF. Institute of Social and Preventive Medicine, University of Bern  
 
Publications (Final report) 
Michel G, Sturdy M, Zwahlen M, Strippoli MPF, von der Weid NX, Kuehni CE. Validating date 
and cause of death information in the Swiss Childhood Cancer Registry against death certificate 
information from the Swiss Federal Office of Statistics. Bern: Dept. of Social and Preventive 
Medicine, University of Bern; Dec 2005. 
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5 Review of activities 2007 – 2009 
5.1 New Database 
During 2006/2007, a new electronic database was developed for the SCCR by Malcolm Sturdy, 
and in June 2007 all data were successfully migrated and final modifications were made on the 
new database. Most data could be migrated automatically. However, certain pieces of informa-
tion needed to be transcribed by hand. This relates for instance to information which had been 
stored as text in comment fields, while the new database stores them as variables in numeric 
format. Also, in several instances, information written in one single text field needed to be sepa-
rated into several fields (for instance, addresses of referring physicians are now stored in sepa-
rate fields for street, house number, town and postcode). The most important modifications were 
done immediately, but other information which is not immediately needed and involves a lot of 
work will be transcribed during the next years. 
The database system 
The SCCR database is an SQL database with an ACCESS user interface. It is hosted on a se-
cure SQL server at the ISPM and allows different users on different computers to access the 
database via the ACCESS user interface. The data is stored encrypted on the server and de-
pending on the user only certain parts of the database can be accessed. Predefined users are: 
System administrator, Data entry (non-anonymous); Data view (non-anonymous); Data view 
(anonymous). 
The database structure 
The database has a relational structure (Figure 8). For every patient one record is created with 
one or more linked records containing address information, information about the paediatrician, 
treating institution, prior disease, late effects, follow-up and external links and non-clinical studies 
(a detailed description of each variable contained in the SCCR database is available in a sepa-
rate document). Every patient can also have one or more tumour records. For every tumour re-
cord one or more records with information about diagnosis address, pathology, cytology and re-
lapse can be created. And for every tumour also one or more therapy record can be created 
which can again have one or more records about information on radiotherapy, surgery, chemo-
therapy and transplantations. 
Detailed descriptions of the variables collected in the database and of the data collection form 
(basic data form) can be obtained from the SCCR (childhoodcancerregistry@ispm.ch or 
kinderkrebsregister@ispm.ch). 
Data protection measures 
The database is stored on a secure server in the ISPM, which is regularly being backed-up. It 
can only be accessed via a personal computer with a personal password. The person data them-
selves are only accessible with an additional password for predefined users. Each access to the 
database is registered and identified. 
Additional documents  
All additional information which the SCCR receives as paper documents (pathology or histology 
reports, other medical reports) are scanned and saved as picture in pdf format (so that the docu-
ments cannot be searched for names). All documents are then saved on the secure, password-
protected server and can be linked, if necessary, to the SCCR record using the patient ID num-
ber. All paper documents are then destroyed. 
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Figure 8 – Relational structure of the SCCR database 
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5.2 New Homepage 
In 2008, a new Homepage for the SCCR was created by Philipp Läuppi, which can be very easily 
updated. It is available in four languages (German, French, Italian and English) and can be ac-
cessed via: 
www.kinderkrebsregister.ch 
www.registretumeursenfants.ch 
www.registrotumouripediatrici.ch 
www.childhoodcancerregistry.ch 
5.3 General exemption for cancer registries from the Swiss Fed-
eral Commission of Experts for Professional Secrecy in Medical 
Research 
Since 1993, the act on professional secrecy for medical professions (Art. 321 StGB) forbids to 
communicate and collect non anonymous data for medical research. Exceptions (described in 
Art. 321bis StGB) are regulated by the Swiss Federal Commission of Experts for Professional 
Secrecy in Medical Research. Such exceptions can be afforded if the research cannot be done 
with anonymous data, if it is impossible or extremely difficult to obtain informed consent, if the 
research is of high public health relevance and if patients are informed of the project and are 
given the opportunity to refuse transfer of their data (right of veto). Three different permissions 
can be given: hospital permissions for single hospitals, special permissions (“Sonderbewilligung”) 
for specific projects, and general registry permissions. 
Between 2004 and 2007, the SCCR had a special exemption (“Sonderbewilligung”). This permis-
sion allowed collecting non-anonymous information on patients from several sites (SPOG clinics). 
For new patients and those still in medical follow-up, written informed consent was collected. Pa-
tients who were no longer in follow-up were informed of the existence of the registry using sev-
eral approaches (newspaper adverts, information via parents and patients organisations). 
While this system worked well for patients treated in Paediatric Cancer Centres from the SPOG, 
it did not allow data exchange with other institutions (other hospitals, cantonal cancer registries, 
pathology laboratories) because it is impossible to obtain informed consent in these situations. 
A research project conducted in the years 2006-2007 described completeness of case registra-
tion in the SCCR by comparing the SCCR dataset with case records in the cantonal cancer reg-
istries (see chapter 2.2.4 and chapter 4.2, project No 6) and found, that during the period 1990-
2004, 22% of cases registered in cantonal cancer registries were not recorded in the SCCR. 
Therefore, patients need to be registered from now on from additional sources as described 
above.   
To enable this, the SCCR applied in April 2007 for a general registry approval by the Swiss Fed-
eral Commission of Experts for Professional Secrecy in Medical Research. This was obtained in 
June 2007 and permits the collection of data on cancer in children and adolescents throughout 
Switzerland without first obtaining written consent. At the time of diagnosis all patients and their 
parents are informed by their doctor about the registry and they can ask their treating doctor not 
to forward their data (veto power). Records of these patients are completely anonymised. 
Huge efforts were made to inform all patients and their families, and all physicians in Switzerland 
about the registry, using various approaches (publications in official medical journals, oral pres-
entations, letters to hospitals, physicians and parents organisations, and publication on the inter-
net and in major newspapers). Information for patients is also available from hospital brochures, 
hospital notice boards, and parents and patients organisations. The patients’ data are kept strictly 
confidential in accordance with the requirements of the Swiss Federal Commission of Experts for 
Professional Secrecy in Medical Research and data with personal information (names, ad-
dresses) are kept separately from the medical information. 
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6 Publications  
Here, only selected publications are reported which have been published between Jan 2005 - 
Jun 2009, which are closely related to the SCCR or SPOG publications of clinical or epidemiol-
ogical content where authors from at least two different SPOG centres contributed. Additional 
publications related to the SCCR and the SPOG can be found on the SCCR website: 
www.childhoodcancerregistry.ch and on the SPOG website: www.spog.ch. 
6.1 Peer-reviewed publications 
2009 1. Adam M, von der Weid NX, Michel G, Zwahlen M, Lutz JM, Probst-Hensch NM, 
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Association of Cancer Registries (ASRT). Which childhood cancer patients fail to access 
specialized care? submitted.  
 
2. Michel G, Rebholz CE, von der Weid NX, Bergstraesser E, Kuehni CE. Psychologi-
cal distress in adult survivors of childhood cancer: the Swiss Childhood Cancer Survivor 
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7 Abbreviations 
AML Acute Myeloid Leukaemia 
BMT Bone Marrow Transplantation 
CANUPIS Childhood Cancer and Nuclear Power Plants in Switzerland 
CHUV Centre Hospitalier Universitaire Vaudois 
CNS Central Nervous System 
DNA Deoxyribonucleic acid 
ENCR European Network of Cancer Registries 
GCCR German Childhood Cancer Registry, Mainz, Germany 
HUG Hôpitaux Universitaires de Genève 
HRQoL Health Related Quality of Life 
IACR International Association of Cancer Registries 
IARC International Association of Research in Cancer 
ICCC-3 International Classification of Childhood Cancer, Third revision 
ICD-10 International Classification of Diseases and Related Health Problems, Tenth revi-
sion 
ICD-O-3 International Classification of Diseases for Oncology, Third edition 
ISPM Institute of Social and Preventive Medicine, Bern 
LCH Langerhans cell histiocytosis 
NICER National Institute for Cancer Epidemiology and Registration, Zurich 
NPP Nuclear Power Plants 
NRCT National Registry of Childhood Tumours, Oxford, England 
PANCARE Pan-European Network for Care of Survivors after Childhood and Adolescent 
Cancers 
PCC Paediatric Cancer Centre 
PNET Primitive Neuroectodermal Tumour 
POG Pediatric Oncology Group 
SCCR Swiss Childhood Cancer Registry 
SCCSS Swiss Childhood Cancer Survivor Study 
SES Socio-economic status 
SFSO Swiss Federal Statistical Office 
SNC Swiss National Cohort 
SPOG Swiss Paediatric Oncology Group 
SSKK Schweizerische Stiftung für klinische Krebsforschung 
STS Soft Tissue Sarcoma 
VSKR 
/ASRT 
Association of Swiss Cancer Registries 
WHO World Health Organisation 
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8 Appendix: Classification of childhood cancer in the 
SCCR 
ICCC-3 
The third edition of the International Classification of Childhood Cancer (ICCC-3) represents the 
standard for presentation of international data on childhood cancer incidence and survival8. It ap-
plies the rules, nomenclature and codes (morphology, topography and behaviour) of the ICD-O-
3. Furthermore, ICCC-3 categories are defined in conformity with international classifications of 
the pathology and genetics of childhood cancers. In the ICCC-3, three hierarchical levels have 
been developed: level one consists of 12 main diagnostic groups and level two of 47 diagnostic 
subgroups. These two levels of the ICCC-3 allow standardised comparison of the broad catego-
ries of childhood tumours. Level three, an optional “extended” classification, comprises two to 
eleven divisions of selected diagnostic subgroups. The division of some diagnostic subgroups, 
e.g. leukaemias and Non-Hodgkin lymphomas, reflects the availability of detailed cytogenetic or 
molecular information that permits homogeneous groups of tumours to be distinguished within 
them and thus allows their separate study. Most childhood cancer registries only use level one 
and two. Only malignant neoplasms are classified in ICCC-3, with the exception of non-malignant 
intracranial and intraspinal tumours. Tumours known to occur only rarely in young patients are 
also included in ICCC-3. The ICCC-3 is used if data are compared with other childhood cancer 
registries. 
ICD-O-3 
The third edition of the International Classification of Diseases for Oncology (ICD-O-3)9 has been 
developed by a working group hosted by IARC/WHO. The morphology code for neoplasm has 
been revised, especially for lymphomas and leukaemias. In contrast to the ICD-10 classification, 
ICD-O-3 uses only one set of four characters for topography (based on the malignant neoplasm 
section of ICD-10). The topography code remains the same for all neoplasms of that site. The 
behaviour code is incorporated as the fifth digit in the morphology field. It identifies whether the 
tumour is malignant, benign, of uncertain or unknown behaviour, in situ, presumed to be primary 
or secondary. ICD-O-3 is used to compare data with general cancer registries. 
ICD-10 
The International Statistical Classification of Diseases and Related Health Problems (ICD)10 per-
mits the systematic recording, analysis, interpretation and comparison of mortality and morbidity 
data collected in different regions and at different time periods. The ICD has become the interna-
tional standard diagnostic classification for all general epidemiological purposes. The ICD-10 
classification comprises three volumes: Volume 1 contains the main classifications; Volume 2 
provides guidance for users of the ICD; and Volume 3 is the alphabetical index to the classifica-
tion. Classification is divided into 21 chapters. The first character of the ICD code is a letter. Each 
letter is associated with a particular chapter, e.g. the letter D is used in both chapters II “Neo-
plasms” and chapter III “Diseases of the blood and blood-forming organs and certain disorders 
involving the immune mechanism”. The topography code in Volume 3 describes the site and the 
behaviour of the neoplasm: malignant, secondary or metastatic, in situ benign or unknown be-
haviour. The morphology codes listed in Volume 1 are the same as those used in the special 
adaptation of the ICD for oncology, the ICD-O (-2). 
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